Related Experiment Videos
[Post-vaccination measles immunity in children on long-term anticonvulsant therapy]
L Popović-Miocinović1, S Smerdel, Z Grubesić
1Zavod za zastitu djece s motornim smetnjama, Zagreb.
Insights
Children on long-term anticonvulsant treatment showed normal measles immunity after vaccination. Their antibody levels and duration of immunity were comparable to healthy children, suggesting revaccination is safe.
Area of Science:
- Immunology
- Pediatrics
- Neurology
Context:
- Measles vaccination is crucial for children.
- Anticonvulsant medications may potentially impact immune response.
- Understanding vaccine efficacy in epileptic children is important for public health.
Purpose:
- To assess seroconversion and duration of immunity following measles vaccination in children on long-term anticonvulsant therapy.
- To compare antibody titers and immunity duration between epileptic children and healthy controls.
Summary:
- A prospective study evaluated 35 children with epilepsy on anticonvulsants and 65 healthy controls 5 years post-measles vaccination (Edmonston-Zagreb strain).
- No significant differences in hemagglutination inhibiting (HI) antibody titers were found between groups at 6 weeks or 5 years post-vaccination.
- No correlation existed between anticonvulsant drug duration/administration and antibody levels or immunity duration.
Impact:
- Findings support the safety and efficacy of measles vaccination in children with epilepsy on anticonvulsants.
- Suggests that children with well-controlled seizures can be safely revaccinated.
- Informs vaccination guidelines and clinical practice for pediatric epilepsy management.
Abstract:
In the prospective study, seroconversion and duration of immunity were examined by studying children on the longterm anticonvulsant treatment 5 years after application of monovaccine against the Edmonston-Zagreb measles. The patient group was composed of 35 children with epilepsy and the control group consisted of 65 children without epilepsy. Average age was 7.5 years for both groups. The examinees were mainly treated with monotherapy, most usually with phenobarbitone, carbamazepine and valproate. Good control of seizures was achieved in all children. Seroconversion was tested 6 weeks following vaccination in all examined children. The levels of titres of hemagglutination inhibiting (HI) antibodies did not differ significantly between examined children and controls (chi 2 = 2.588 p > 0.05). Nor did the correlation exist between the length of antiepileptic drug administration and the level of antibody titres (chi 2 = 0.75 p < 0.05). Five years after the vaccination, the level of titres of HI antibodies in epileptic patients and controls showed no statistically significant difference (chi 2 = 2.42 p < 0.05). There was also no correlation between the duration of receiving anticonvulsants and duration of immunity (chi 2 = 0.25 p < 0.05). The children with good control of seizures can be revaccinated, as well as the healthy children, 5 years after the primary vaccination.